Global Rivaroxaban Market Outlook 2018: Industry Analysis with Future Forecast till 2025

This report studies the global Rivaroxaban market status and forecast, categorizes the global Rivaroxaban market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.

The global average price of Rivaroxaban is in the decreasing trend, from 5.62 USD/Unit in 2011 to 5.34 USD/Unit in 2015. With the situation of global economy, prices will be in slowly decreasing trend in the following five years.

Bayer is the only supplier of Rivaroxaban enjoying production market share100% in 2015 and it will still in this situation until 2023.

The global Rivaroxaban market is valued at 5860 million US$ in 2017 and will reach 11000 million US$ by the end of 2025, growing at a CAGR of 8.2% during 2018-2025.

Request Sample Copy of Report @ https://www.qyresearch.com/sample-form/form/506001/global-rivaroxaban-market

The major manufacturers covered in this report

Bayer

J&J

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering

North America

Europe

China

Japan

Southeast Asia

India
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

2.5 mg

10 mg

15 mg

20 mg

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

Acute Coronary Syndrome (ACS)

Venous Thromboembolism (VTE)

Benefits of Purchasing QY Research Report
• Analyst Support: Get you query resolved from our expert analysts before and after purchasing the report
• Customer’s Satisfaction: Our expert team will assist with all your research needs and customize the report
• Inimitable Expertise: Analysts will provide deep insights about the reports
• Assured Quality: We focus on the quality and accuracy of the report

Buy Full Report Now, Report delivery time within 24 hours @ https://www.qyresearch.com/settlement/pre/f9deea78a89b8c6fe9237f3a64ef32a2,0,1,Global%20Rivaroxaban%20Market%20Research%20Report%202018

About Us:
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Contact US:
QY Research, INC.
17890 Castleton,
Suite 218,
Los Angeles, CA – 91748
USA: +1 626 295 2442
Email: enquiry@qyresearch.com
Web: http://www.qyresearch.com

This release was published on openPR.